Abstract

Objective
To investigate therapeutic effects of annexin A1 (anxA1) on atherogenesis in LDLR⁻/⁻ mice.

Methods
Human recombinant annexin A1 (hr-anxA1) was produced by a prokaryotic expression system, purified and analysed on phosphatidylserine (PS) binding and formyl peptide receptor (FPR) activation. Biodistribution of ⁹⁹ᵐTc-Technetium-hr-anxA1 was determined in C57Bl/6J mice. 12 Weeks old LDLR⁻/⁻ mice were fed a Western Type Diet (WTD) during 6 weeks (Group I) or 12 weeks (Group P). Mice received hr-anxA1 (1 mg/kg) or vehicle by intraperitoneal injection 3 times per week for a period of 6 weeks starting at start of WTD (Group I) or 6 weeks after start of WTD (Group P). Total aortic plaque burden and phenotype were analyzed using immunohistochemistry.

Results
Hr-anxA1 bound PS in Ca²⁺-dependent manner and activated FPR2/ALX. It inhibited rolling and adherence of neutrophils but not monocytes on activated endothelial cells. Half lives of circulating ⁹⁹ᵐTc-hr-anxA1 were <10 minutes and approximately 6 hours for intravenously (IV) and intraperitoneally (IP) administered hr-anxA1, respectively. Pharmacological treatment with hr-anxA1 had no significant effect on initiation of plaque formation (-33%; P = 0.21)(Group I) but significantly attenuated progression of existing plaques of aortic arch and subclavian artery (plaque size -50%, P = 0.005; necrotic core size -76% P = 0.015, hr-anxA1 vs vehicle) (Group P).
Conclusion
Hr-anxA1 may offer pharmacological means to treat chronic atherogenesis by reducing FPR-2 dependent neutrophil rolling and adhesion to activated endothelial cells and by reducing total plaque inflammation.

Introduction
Atherosclerosis is a systemic chronic inflammatory disease affecting the vascular wall of arteries and is the major cause of morbidity and mortality in both developed and developing countries. The disease is characterized by confined manifestations of atherosclerotic lesions in the arterial vessel wall that may develop into unstable plaques causing adverse outcomes over time [1–3]. Unstable plaques are characterized by abundant presence of inflammatory cells, a large necrotic core and a thin fibrous cap [4]. Inflammatory cells are considered key players in initiation of- and progression to an unstable plaque [5,6]. Activated neutrophils act as important effectors and regulators of inflammation through their ability to produce a myriad of effector molecules including cytokines, chemokines and angiogenic factors [7]. Reducing recruitment of neutrophils to the inflamed arterial vessel wall by neutrophil-specific antibodies and gene-deletions of chemokines and their receptors, suppresses arterial lesion development in mouse models of atherosclerosis [8–10].

Annexin A1 (anxA1) is a member of the multigene annexin family [11] with potent anti-inflammatory activity [12]. The polypeptide chain of anxA1 comprises a C-terminal core domain, which is conserved amongst all members of the family and harbors the Ca2+/phospholipid binding sites, and an N-terminal tail that varies between annexin members. The N-terminal tail of anxA1 can interact with the receptor for formylated peptides (FPR2/ALX) [11,13–16]. In absence of calcium and a phospholipid surface, the tail is concealed within the core domain. However, upon membrane binding anxA1 changes conformation and exposes the N-terminus at the surface enabling interaction with FPR-2 [15]. AnxA1-FPR2 interaction results in inhibition of neutrophil recruitment to inflamed sites [17]. Alternatively, proteolysis can cause release of the N-terminal peptide [18], which then can interact with FPR1 and 2 evoking anti-inflammatory activity [19]. Pharmacological treatment of inflammation using anxA1 and its N-terminal peptide has been studied in mouse models of neutrophil-dependent edema [20], cardiac ischemia-reperfusion injury [21,22] and acute peritonitis [23], however, hitherto not in atherosclerosis.

Recently it was shown by gene-knockout strategies that the anxA1-FPR2/ALX axis contributes to atherogenesis in apoE−/− mice by mediating recruitment of inflammatory cells to the atherosclerotic plaque [24]. In this paper we studied pharmacological effects of recombinant human recombinant anxA1 (hr-anxA1) on the initiation of atherosclerosis and the progression of established atherosclerotic plaques in an LDLR−/− mouse model. We demonstrate that hr-anxA1 has no significant effect on initiation of early plaque development, but significantly attenuates progression of existing lesions to unstable plaques.

Methods
Design, production and purification of recombinant human (hr)-anxA1

C DNA coding for hr-anxA1 was amplified by polymerase chain reaction (PCR) using primers: 5’-GGTATCGAGGGAAGGCAATGGTAGTACGAAATTTCC-3’ and 5’-GCTCGAGCTAAATTAAGCTTTAGGTTTCCACAAAGAGC-3’. The primers introduced Stu-I and Hind-III.
restriction sites, required for the ligation into the expression vector pQE30Xa (Qiagen). His-tagged hr-anxA1 was produced according to previously published protocol for anxA5 [25]. In short, E. Coli (SG13009 pREP4) (Novagen) were fermented in Luria-Bertani broth medium supplemented with Ampicillin (50μg/ml, Roche), Kanamycin (30μg/ml, Gibco) and 0.5% glycerol. At OD₄₅₀ of >6, over-expression of the protein was initiated by addition of 5mM isopropyl β-D-1-thiogalactopyranoside (IPTG, Eurogentec). Proteins were purified by IMAC. Purity and homogeneity were assessed by silver-stained SDS-PAGE, western blotting and MALDI-TOF/TOF analysis.

**Endotoxin determination**

Endotoxin was determined with the Endosafe-PTS (Charles-River) according to manufacturer’s protocol. Purified protein preparations containing <1 unit/ml endotoxin were used for experiments.

**Ellipsometry**

PS-binding property of purified hr-anxA1 was determined by ellipsometry using a bilayer of 20 mole% dioleoyl-phosphatidylserine / 80 mole% dioleoyl-phosphatidylcholine (20 mole% DOPS/80 mole% DOPC; Avanti Polar Lipids, Alabaster, AL, USA) as described previously [26].

**Cells**

Primary bone marrow derived monocytes were isolated as described before [27]. Mice were anesthetized with 5% isoflurane before sacrifice by cervical dislocation. Cells were grown for 8 days in RPMI 1640 containing 10 mM Hepes, 10% heat inactivated fetal bovine serum (FBS, Gibco-BRL), 15% L929-cell conditioned medium, 100U/ml Penicillin (Gibco-BRL) and 100 μg/ml Streptomycin (Gibco-BRL) [28].

The human monocytic cell line THP-1 (ATCC, Manassas, USA), was cultured in RPMI 1640 without color indicator (Gibco-BRL, Invitrogen, USA) supplemented with 2mM glutamine (Gibco-BRL, Invitrogen), 10% heat-inactivated FBS, 100units/ml penicillin and 100μg/ml streptomycin.

Polymorphonuclear leukocytes (PMN) were isolated from blood collected into 3.2% sodium citrate, diluted 1:1 in RPMI 1640 (Sigma-Aldrich) before separation through a double-density gradient as described previously [19].

Confluent human umbilical vein endothelial cells (HUVEC, PromoCell, C12203) were grown to a monolayer in a μ-slide (Ibidi, 80666, Germany) before flow experiments.

**Calcium mobilization and flow-chamber assay**

Receptor binding studies were performed on FPR-2 transfected HEK293 cells as described previously [29]. Leukocyte rolling and adhesion flow chamber experiments were performed as described previously [19]. Each flow experiment consisted in total of a 10 second recording at 3.3 frames per second. Cells of all 32 frames were counted: adhering cells were stationary in all frames, while rolling cells were defined as all interacting non-stationary cells.

**In vitro internalization of hr-anxA1**

Binding and internalization of fluorescently labeled hr-anxA1 by apoptotic Jurkat cells was visualized with confocal laser scanning microscopy (CLSM) as described previously [30].
Animals

All animal experiments have been conducted under a protocol approved by the ethics committee for animal experiments of Maastricht University (DEC 2012–068) and comply with ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines and followed the European Union Directive (2010/63/EU). All animal experiments were conducted as humane as possible, a total of 52 animals were used. For pharmacological treatment with hr-anxA1, 12 weeks old LDLR<sup>−/−</sup> mice were fed a Western type diet (WTD, 0.15% cholesterol) (AB diets 4021.13) for 6 weeks (group I, n = 12) or 12 weeks (group P, n = 12). Mice received 1 mg/kg hr-anxA1 or PBS (control) 3 times per week via intraperitoneal injection during 6 weeks initiating at the start of WTD (group I) or 6 weeks after start of WTD (group P). Mice were sacrificed under anesthesia of 5% isoflurane by vena cava puncture after subcutaneous injection of 0.1 mg/kg Buprenorphine (Temgesic). Aortic arches including major branch points were dissected, fixed in 1% PFA o/n, paraffin embedded and sectioned at 4 μm thickness. Total plaque area was determined for the entire aortic arch and the brachiocephalic, carotid and subclavian arteries using standard hematoxylin/eosin (H&E) staining on every fifth section, and analyzed with ImageJ Software (v1.45). Progression and stability of plaques was scored on the following parameters: neutrophil and macrophage content, apoptosis and necrosis, cap thickness and calcification status (see S1 and S2 Tables).

Nuclear imaging, biodistribution and blood clearance

Purified His-tagged hr-anxA1 was radiolabeled with technetium-99m (99mTc(CO)<sub>3</sub>-His-anxA1) using the IsoLink tricarbonyl labeling method (Covidien, Petten, The Netherlands) as described previously for His-anxA5 [31]. Nuclear imaging, blood clearance and biodistribution were performed using 12 weeks old LDLR<sup>−/−</sup> mice (Charles-River). Biodistributions and blood clearances of IV and IP injected 100 MBq 99mTc(CO)<sub>3</sub>-His-anxA1 were determined. To exclude any dietary effect on the biodistribution or blood clearance, mice were put on WTD 2 weeks prior to the experiment. Total body single photon emission tomography (SPECT) imaging was performed 45 minutes post-injection as previously described [32].

Flow cytometry of blood and bone marrow cells

Single cell suspensions were prepared and stained with anti-CD3, -CD4, -CD8a, -CD11b, -CD115, -Ly6C, -Ly6G, -B220, -NK1.1, or isotype control IgG. Antibodies conjugated to FITC, PE, APC, Cy7, eFluo450, or PerCP (all BD Biosciences) were used and cells were analyzed using a FACS-Canto II and FACSDiva Software (V6.1.3, BD Biosciences).

Anti-hr-anxA1 antibody formation

Blood was collected in 3.2% sodium citrate and plasma was collected by centrifugation. A 96-well plate was coated with 5 μg/ml hr-anxA1 in 0.1M carbonate buffer (pH 9.5) o/n and blocked with 3% non-fat dry milk in phosphate buffered saline (PBS). Ten times diluted plasma was added and incubated 1h at 37°C, rabbit-α-human anxA1 antibody was used as positive control. HRP-labeled rat-α-mouse-IgG (Dako, P0161) was added and incubated 1h at 37°C. Chromogenic substrate tetramethyl benzidine (TMB) was measured at 450nm.

Endogenous thrombin potential (ETP)

ETP was determined in plasma containing 3.3 μM corn trypsin inhibitor (CTI) using 7 pM of tissue factor, 60 μM of phospholipids (20%PS/60%PC/20%PE), 420 μM fluorogenic substrate and 8.2 mM Ca<sup>2+</sup> [33].
Immunohistochemistry

Immunohistochemistry was performed using antibodies against MAC-3 (BD Biosciences, clone M3/84, 553322) for all macrophages, iNOS (Abcam, AB3523) for M1-polarized and Ym1 (kind gift from professor Christoph Binder, Vienna, Austria) and CD206 (ITK diagnostics, 141702) for M2-polarized macrophages.

Statistical analysis

All data is presented as mean ± SEM. Normality was tested using the Shapiro-Wilk normality test with GraphPad Prism 5.0 software. Statistical significance between two groups was tested by unpaired two tailed student’s t-test. A value of P < 0.05 was considered statistically significant. P-values are indicated in the tables and figures by asterisks as follows *P < 0.05, **P < 0.005, ***P < 0.001.

Results

Physical and biological characterization of hr-anxA1

The N-terminal tail mediates anti-inflammatory activities of anxA1 and contains protease-sensitive sites [29]. We used the expression vector pQE30Xa that introduced a His-tag upstream of the N-terminal tail, which was cleaved off after purification by FXa. In order to verify that our procedure yielded full-length recombinant product, purified hr-anxA1 was subjected to structural analyses including MALDI TOF/TOF, silver stained SDS-PAGE and Western blotting (S1 Fig) and tryptic digestion. These analyses confirmed the production and purification of full-length hr-anxA1 with a purity of >95%. Hr-anxA1 was stable for at least 1 year if stored in HEPES/NaCl pH7.4 at 4°C. Biological functionality of the N-terminal tail and Ca²⁺-dependent PS-binding of the C-terminal core were intact as assessed by the calcium flux induced in FPR-2 transfected HEK-293 cells and ellipsometry respectively (Fig 1A and 1Band S2 Fig). Furthermore, hr-anxA1 was internalized by Jurkat cells in the early phase of apoptosis in a PS-binding and FPR-dependent manner. This was demonstrated with FPR-inhibitors cyclosporine H (CsH) and WRW4 using flow cytometry (Fig 1C) and confocal microscopy (Fig 1D) and underscored by absence of internalization if hr-anxA1 lacks its N-terminus (S3 Fig). AnxA5 internalization, which depends on PS-binding and trimerization [34,35], was affected by neither inhibitor (Fig 1C). Finally, hr-anxA1 significantly inhibited rolling and adhesion of polymorphonuclear cells (50% and 63%, respectively) over a monolayer of TNFα-activated HUVECs (Fig 1E) while it had no effect on rolling and adhesion of THP-1 monocytes (Fig 1F and 1G).

Determination of in vivo administration route of hr-anxA1

In order to establish the preferred route of administration, biodistribution and blood clearance were determined for IV and IP administered ⁹⁹ᵐ⁹-Tc(CO)₃-His-anxA1. ⁹⁹ᵐ⁹-Tc(CO)₃-His-anxA1 had radiochemical purity of approximately 90% and eluted as a single peak on RP-HPLC (S4A Fig). IV administered ⁹⁹ᵐ⁹-Tc(CO)₃-His-anxA1 was cleared by the kidneys, liver and lungs. IP administered ⁹⁹ᵐ⁹-Tc(CO)₃-His-anxA1 was gradually released into the blood circulation, peaked at 50 min post injection and then gradually decreased through clearance by the kidneys and liver (S4B–S4D Fig) with t₁/₂ of approximately 6 hours. About 0.5% of injected dose per gram (ID/g) anxA1 remained in the circulation 24 hours post injection. On basis of pharmacokinetics we decided to administer hr-anxA1 three times per week IP as treatment.
Administration of hr-anxA1 does not alter baseline characteristics of LDLR−/− mice

Treatment of LDLR−/− mice on WTD with hr-anxA1 had no effect on body weight, circulating cholesterol and triglyceride levels and procoagulant activity of blood plasma (Table 1). 6 weeks of IP administration of hr-anxA1 did not cause generation of anti-hr-anxA1 antibodies (data not shown).

Hr-anxA1 has no significant effect on early plaque development

Pharmacological treatment with hr-anxA1 starting at start of WTD (Group I) was without significant effect on plaque growth during 6 weeks of treatment (total plaque size 0.024±0.019 mm³ versus 0.016±0.010 mm³, control versus hr-anxA1, P = 0.21). Plaque growth was comparable for hr-anxA1 treated and vehicle treated mice at different aortic sites (Fig 2A and 2B). Both hr-anxA1 and vehicle treated mice developed intimal xanthoma (IX) and small foam cell lesions (SL) (Fig 2C) with infiltrated macrophages in comparable proportion, indicating that hr-anxA1 affects neither onset of IX formation nor their transition into SL in LDLR−/− mice.
under atherogenic pressure. 70% to 80% of the endothelium of the aortic arch was activated as evidenced by ICAM-1 expression. Pharmacological treatment with hr-anxA1 had no significant effect on ICAM-1 expression (Fig 2D and 2E).

**Hr-anxA1 attenuates progression into advanced plaques**

Hr-anxA1 treatment of mice with established plaques (Group P) caused a significant inhibition of total plaque growth (0.13±0.080 mm³ versus 0.065±0.031 mm³, control versus hr-anxA1, -50%, P = 0.005), which was most pronounced in the arch and subclavian artery (Fig 3A and 3B). Individual plaque progression was further scored (see S1 and S2 Tables). This classification showed that hr-anxA1 treated mice predominantly developed early IX and SL, while the control treated mice had already IL and AL development (Fig 3C). Interestingly, aortic endothelium lost ICAM-1 expression (Fig 3D and 3E) in control mice receiving a WTD during 12 weeks as compared to control mice fed a WTD during 6 weeks (Fig 2D and 2E). Hr-anxA1 treatment further reduced endothelial ICAM-1 expression in Group P mice (Fig 3D and 3E), indicating a positive pharmacological effect of hr-anxA1 on resolution of inflammation. Hr-anxA1 treatment did not change the macrophage and smooth muscle cell content relative to lesion size as compared to the vehicle treated lesions (Fig 3F–3I). Blood analysis revealed significant increase in proportion of granulocytes of circulating leukocytes, while bone marrow showed no differences in leukocyte composition between control and hr-anxA1 treated mice (Table 2).

**Hr-anxA1 does not affect macrophage polarization in atherosclerotic plaque**

Recently we demonstrated that endogenous anxA1 contributes to resolution of chronic inflammation in a mouse model of nonalcoholic steatohepatitis (NASH) through stimulation of IL-10 production and down-modulation of M1 polarization [36]. Therefore we studied whether hr-anxA1 could influence polarization of macrophages in developed atherosclerotic plaques (P). Quantification of M1 polarization marker iNOS (Fig 4A and 4B) showed no differences between control and anxA1 treated plaques. Staining was diffuse throughout the entire lesion, whereas the non-immune immunoglobulin staining was negative. We did not detect any marker of M2 polarization in the atherosclerotic lesions of both groups using antibodies against Ym1 (Fig 4C and 4D). This indicates that the lesions are predominantly occupied by M1 macrophages. Treatment of bone marrow-derived macrophages (BMDM) with hr-anxA1 *in vitro* did not affect IL-12, TNFα and NO release as compared to control (S6A and S6B Fig). IL-10 remained below detection limit in hr-anxA1 treated and untreated BMDM.

### Table 1. Baseline characteristics of control and hr-anxA1 treated mice.

| Group | Ctrl | hr-anxA1 |
|-------|------|----------|
| Age (wks) | 18 ±0.5 | 18 ±0.5 |
| Weight (g) | 26.2 ±1.9 | 25.8 ±1.6 |
| Cholesterol (mM) | 25.2 ±2.9 | 24.6 ±3.9 |
| Triglycerides (mM) | 3.3 ±0.6 | 3.2 ±0.8 |
| Coagulation | |
| ETP (nM.min⁻¹) | 1376 ±104.0 | 1312 ±46.3 |
| Peak height (nM) | 185.3 ±6.7 | 190.8 ±11.0 |

| Group | Ctrl | hr-anxA1 |
|-------|------|----------|
| Age (wks) | 24 ±0.5 | 24 ±0.5 |
| Weight (g) | 29.2 ±2.4 | 27.9 ±1.5 |
| Cholesterol (mM) | 28.3 ±2.7 | 26.9 ±2.9 |
| Triglycerides (mM) | 3.3 ±0.6 | 3.6 ±0.5 |
| doi:10.1371/journal.pone.0130484.t001
Discussion

AnxA1 has anti-inflammatory and pro-resolving properties causing dampening of inflammation in several animal models of acute and chronic inflammation [36–38]. Recently it was demonstrated that the anxA1-FPR2 axis suppresses atherogenesis in the apoE-/- mouse model [24]. In vivo administration of anxA1’s N-terminal peptide Ac2-26 inhibited myeloid interaction with endothelium in an FPR2-dependent manner during short-term experiments [24]. Long-term treatment with Ac2-26 peptide coupled to collagen IV-targeting nanoparticles reduced inflammation of advanced plaques of LDLR-/- mice in an FPR2-dependent manner [39]. We hypothesized that full length anxA1 reduces atherogenesis if administered to LDLR-/- mice on WTD. Therefore we produced recombinant human anxA1 (hr-anxA1) and thoroughly inspected integrity and functional properties of the N-terminal tail and C-terminal

Fig 2. Hr-anxA1 has no significant effect on early plaque development. 12 weeks old mice were fed WTD during 6 weeks. Hr-anxA1 treatment started at start of WTD. (A) Representative H&E staining of aortic arches after 6 weeks of treatment. (B) Treatment with hr-anxA1 did not affect plaque burden in the arch and subclavian (SA) brachiocephalic (BCA) and left common carotid artery (CA). (C) Individual plaque stability and progression was scored on following parameters: neutrophil and macrophage content, apoptosis and necrosis, cap thickness and calcification status (see S1 and S2 Tables). Hr-anxA1 treatment had no effect on early plaque stability and progression. (D, E) Hr-anxA1 treatment had no effect on endothelial ICAM-1 expression of IX and SL lesions. IX: intimal xanthoma; SL: small lesion; IL: intermediate lesion; AL: advanced lesion. All values are represented as mean ±SEM, n = 12 animals per group. Panel A: 40x magnification, scale bar represents 500μm. Panel D: 200x magnification, scale bar represents 100μm.

doi:10.1371/journal.pone.0130484.g002
core. Both are essential to the anti-inflammatory properties of anxA1, since this requires both interaction with FPR2 and binding to PS, respectively [22]. Hr-anxA1 possessed both functional properties with sufficient shelf-stability to perform series of in vivo experiments. Secondly, pharmacokinetics and biodistribution of hr-anxA1 were determined to select the preferred route of administration. Intravenous administered hr-anxA1 was cleared rapidly from circulation with $t_{1/2}$ of $<10$ min. This rapid pharmacokinetic is comparable with half-life reported for anxA5, another member of the annexin family [40]. Biodistribution showed accumulation of hr-anxA1 in kidneys but also in liver and lungs. Currently we have no explanation for the latter phenomenon but this could indicate clearance via the reticula-endothelial system. Pharmacokinetics and biodistribution of intraperitoneally administered hr-anxA1 revealed release of hr-anxA1 into circulation during a longer period of time with a peak at 50 min post

**Fig 3. Hr-anxA1 attenuates progression into advanced plaques.** (A) 12 weeks old mice were fed WTD 12 weeks. During the last 6 weeks mice were treated with hr-anxA1 or vehicle (ctrl). (A) Representative H&E staining of aortic arches. (B) Treatment with hr-anxA1 significantly reduced total plaque burden in the inner arch (arch) and subclavian artery (SA) but not in the brachiocephalic (BCA) and left common carotid artery (CA). (C) Individual plaque progression was scored on following parameters: neutrophil and macrophage content, apoptosis and necrosis, cap thickness and calcification status (see S1 and S2 Tables). (D, E) Endothelial ICAM-1 expression was reduced in early plaque development (IX/SL) after anxA1 treatment. (F, G) Macrophage and (H, I) smooth muscle cell content were comparable between anxA1 and vehicle treated controls. IX: intimal xanthoma; SL: small lesion; IL: intermediate lesion; AL: advanced lesion. All values are represented as mean ±SEM, n = 12 animals per group. Panel A: 40x magnification, scale bar represents 500 µm; Panel D,F: 100x magnification, scale bar represents 200 µm; Panel H: 200x magnification, scale bar represents 100 µm.

doi:10.1371/journal.pone.0130484.g003
Table 2. Flow cytometry analysis of blood and bone marrow.

|                          | Ctrl (n = 7) | hr-anxA1 (n = 6) | P     |
|--------------------------|-------------|-----------------|-------|
| **Blood (% of viable)**  |             |                 |       |
| B-cells                  | 46.9 ±9.5   | 33.8 ±15.8      | n.s.  |
| NK-cells                 | 4.1 ±0.4    | 4.0 ±0.3        | n.s.  |
| Granulocytes             | 18.2 ±7.1   | 35.0 ±18.8      | 0.039 |
| Monocytes                | 9.9 ±4.5    | 10.6 ±2.5       | n.s.  |
| Ly6C<sub>low</sub> (% of mono) | 22.1 ±4.2 | 18.5 ±10        | n.s.  |
| Ly6C<sub>medium</sub> (% of mono) | 10.7 ±2.0 | 9.7 ±1.8        | n.s.  |
| Ly6C<sub>high</sub> (% of mono) | 67.2 ±5.6 | 71.8 ±8.3       | n.s.  |
| T-Cells                  | 14.2 ±1.8   | 12.1 ±4.9       | n.s.  |
| CD4+ (% of T-cell)       | 41.9 ±1.6   | 45.3 ±6.4       | n.s.  |
| CD8+ (% of T-cell)       | 58.1 ±1.6   | 54.7 ±6.4       | n.s.  |
| **Bone marrow (% of viable)** |         |                 |       |
| B-cells                  | 17.8 ±1.4   | 19.6 ±5.2       | n.s.  |
| NK-cells                 | 1.1 ±0.2    | 1.0 ±0.2        | n.s.  |
| Granulocytes             | 36.7 ±2.0   | 30.2 ±9.1       | n.s.  |
| Monocytes                | 14.8 ±1.5   | 14.3 ±2.0       | n.s.  |
| Ly6C<sub>low</sub> (% of mono) | 10.6 ±2.5 | 9.9 ±2.8        | n.s.  |
| Ly6C<sub>medium</sub> (% of mono) | 51.1 ±6.2 | 46.2 ±9.4       | n.s.  |
| Ly6C<sub>high</sub> (% of mono) | 38.2 ±7.8 | 43.8 ±10.6      | n.s.  |
| T-cells                  | 0.5 ±0.2    | 0.7 ±0.3        | n.s.  |
| Undefined                | 25.6 ±1.8   | 30.1 ±5.0       | n.s.  |

doi:10.1371/journal.pone.0130484.t002

Fig 4. Hr-anxA1 does not affect macrophage polarization in atherosclerotic plaque. (A) Representative staining for M1 macrophage specific marker iNOS. Black arrows indicate fully committed M1 macrophages, white arrows indicate iNOS negative macrophages. (B) Quantification of iNOS-staining indicates no difference between control and anxA1 treated animals. (C) Representative staining of M2 specific marker Ym1. Both control and hr-anxA1 treated mice were negative for Ym1. (D) Staining of Ym1 positive cells in the spleen indicating functionality of anti-Ym1 antibody. All values are represented as mean ±SEM, n = 12 animals per group. Panel A: 200x magnification, scale bar represents 100µm; panel D: 40x and 400x magnification, scale bar represent 500µm and 50µm respectively.

doi:10.1371/journal.pone.0130484.g004
administration. Here, clearance from circulation occurred predominantly by kidneys. Based on pharmacokinetics and biodistribution we decided to administer hr-anxA1 by IP injection with a dosing regime of 3 times per week 1 mg/kg. The dosing regime was extrapolated from published results (38) and should be optimized by future studies.

AnxA1 suppresses and resolves inflammation predominantly through targeting neutrophils [12]. Evidence is accumulating that neutrophils play important roles in atherogenesis and contribute to initiation, progression and destabilization of atherosclerotic plaques [41–44]. Our experiments showed that treatment with hr-anxA1 was without significant effect on initiation of plaque formation but inhibited significantly plaque progression. This was most pronounced in the inner curvature of the arch and in the subclavian artery. Currently we have no explanation for the lack of a significant effect of hr-anxA1 on the early stage of atherogenesis but this could be related to the model of the LDLR⁻/⁻ mouse on WTD.

The N-terminal peptide of anxA1 (Ac2-26) lowers expression of ICAM-1 by atherosclerotic lesional cells [39] and reduces affinity of neutrophils and monocytes for ICAM-1 and VCAM-1 when they are activated by CCL5 [45]. ICAM-1 is a strong regulator of neutrophil adhesion and transmigration [46]. We show that full-length anxA1 reduces endothelial ICAM-1 expression in a similar manner. In addition, anxA1 can inhibit adhesion of neutrophils to endothelial cells directly [19,47] and diminish their transmigration across the endothelium [48] by engaging via its N-terminal tail with the FPR2/AXLR [14]. Concordant with a previous report [48] we observed that hr-anxA1 induced a relative increase of circulating granulocytes, which is an indication for hr-anxA1 induced neutrophil demargination and inactivation. A similar effect has been reported for treatment with glucocorticoids [49], of which anxA1 is considered to be a down-stream effector [12]. Interestingly, our in vivo results show that although hr-anxA1 treatment did not affect intimal xanthoma and small lesion formation it afforded substantial inhibitory effects on progression of small lesions towards advanced lesions. Recent observations showed that hyper-activation and life prolongation of neutrophils through knocking out CXCR4 affect progression rather than initiation of atherosclerosis [42]. Taken together our findings demonstrate that pharmacological treatment with full length anxA1 suppresses atherogenesis in the LDLR⁻/⁻ mouse model. The neutrophil has been reported as an effector of anxA1’s anti-inflammatory actions. However, hr-anxA1 may dampen the inflammatory process of atherosclerosis by acting on the plaque macrophage. We reported recently that anxA1 can polarize liver macrophages towards the anti-inflammatory M2 phenotype [50]. Macrophage polarization is an important contributor to atherogenesis [51,52]. M2 polarized macrophages diminish plaque inflammation and inhibit plaque progression [53]. However, we found no evidence of macrophage skewing in the atherosclerotic lesions of our mice. We cannot exclude that hr-anxA1 modulates macrophage function in other ways. For example hr-anxA1 may enhance efferocytosis by macrophages. Apoptosis and efferocytosis determine rate of plaque progression and plaque phenotype [54,55]. Hr-anxA1 can act as a bridging molecule between the apoptotic cell and the macrophage and, thereby, it stimulates efferocytosis [22,56,57] and reduces release of the pro-inflammatory IL-6 and TNF-α [58]. In our experiments we observed that atherosclerotic plaques treated with hr-anxA1 had smaller necrotic cores, suggestive of enhanced efferocytosis.

We conclude that progression of atherosclerosis can be attenuated pharmacologically with hr-anxA1 in a murine model of atherosclerosis. These findings may open novel avenues to treat the chronic inflammatory disease atherosclerosis.

Supporting Information
S1 Fig. Production and purification of hr-anxA1. (A) MALDI-TOF/TOF analysis shows a molecular weight of 38.5kDa for purified hr-anxA1, which is in concordance with the
theoretical molecular weight of full-length anxA1. Bis-protonated hr-anxA1 and hr-anxA1 dimers are represented on the spectrum as peaks of 19.2kDa and 77.2kDa respectively. (B) Representative image of 50ng purified hr-anxA1 (1) and His-anxA1 (2) on silver-stained SDS-PAGE for total protein and (C) Western blotting with an α-anxA1-antibody (n ≥ 5 purifications) M = broad range protein marker.

S2 Fig. Ellipsometry analysis of phospholipid binding properties. (A) Ca$^{2+}$-dependent binding curves of 1 µg/ml hr-anxA1 and 1 µg/ml anxA5 binding to 5/95, (B) 10/90 and (C) 20/80 mol% PS/PC bilayer as measured by ellipsometry.

S3 Fig. MALDI-TOF/TOF analysis of truncated hr-anxA1. Mass spectrometry analysis of truncated hr-anxA1 shows a molecular weight of 35.8kDa, which means truncation occurred between Thr$^{23}$ en Val$^{24}$.

S4 Fig. Determination of in vivo administration route of hr-anxA1. (A) HPLC analysis of radio-labeled His-anxA1 ($^{99m}$Tc(CO)$_3$-His-anxA1) shows a radiochemical purity of >95% and specific retention time of approximately 18 minutes. (B) SPECT image 45 minutes after intraperitoneal (IP) and intravenous (IV) injection of $^{99m}$Tc(CO)$_3$-His-anxA1. White arrows indicate site of injection, red arrows indicate kidneys and green arrows indicate lungs. Rapid renal clearance and uptake in the lungs was observed in the IV injected mice, whereas IP injection mice show peritoneal localization. (C) Time courses of blood levels of $^{99m}$Tc(CO)$_3$-His-anxA1 were determined by γ-counting. (D) Biodistribution was determined by weighing and γ-counting of organs dissected 3 and (E) 24 hours post-injection. All values are represented as mean ± SEM, n = 6 animals per group.

S5 Fig. Correlation of 2 and 3 dimensional plaque sizes. Plaque volumes were determined and correlated with plaque areas of the section having the largest plaque area.

S6 Fig. Bone marrow derived macrophage response to anxA1. Bone marrow derived monocytes were differentiated to macrophages and stimulated with 1 or 10 µg/ml anxA1. (A) Release of IL-12 and TNF-α and (B) nitric oxide were measured and showed no differences between control and anxA1 addition. All values are represented as mean ± SEM (n = 4 animals).

S1 Table. Quantification of plaque progression.

S2 Table. Definition of plaque progression score.

Acknowledgments

ETP measurements were performed by S. Thomassen (Department of biochemistry, Maastricht University). Correspondence and requests for materials should be addressed to C. Reutelingsperger.
Author Contributions
Conceived and designed the experiments: DHMK MLC MP EALB LJS CPM. Performed the experiments: DHMK MLC BAGW MDS MB EV SB LJS. Analyzed the data: DHMK MLC LJS. Contributed reagents/materials/analysis tools: MP EALB LJS CPM. Wrote the paper: DHMK MLC MP EALB LJS CPM.

References
1. Virmani R, Burke AP, Kolodgie FD, Farb A (2002) Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 15: 439–446. PMID: 12476646
2. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115–126. PMID: 9887164
3. Kusters DH, Tegtmeier J, Schurgers LJ, Reutelingsperger CP (2012) Molecular imaging to identify the vulnerable plaque—from basic research to clinical practice. Mol Imaging Biol 14: 523–533. doi: 10.1007/s11307-012-0586-7 PMID: 22983911
4. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R (2013) Update on acute coronary syndromes: the pathologists’ view. Eur Heart J 34: 719–728. doi: 10.1093/eurheartj/ehs411 PMID: 23242196
5. Moore RJ, Tabas I (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519–531. doi:10.1038/nri3024 PMID: 21785456
6. Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519–531. doi: 10.1038/nri3024 PMID: 21785456
7. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122: 1837–1845. doi: 10.1161/ CIRCULATIONAHA.110.961714 PMID: 20956207
8. de Jager SC, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, et al. (2013) Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol 33: e75–e83. doi: 10.1161/ATVBAHA.112.300857 PMID: 23288165
9. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, et al. (2008) Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102: 209–217. PMID: 17991882
10. Perretti M, D’Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9: 62–70. doi: 10.1038/nri2470 PMID: 19104500
11. Raynal P, Pollard HB (1994) Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1197: 63–93. PMID: 8155692
12. Perretti M (2003) The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol Sci 24: 574–579. PMID: 12610094
13. Bena S, Brancalone V, Wang JM, Perretti M, Flower RJ (2012) Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem 287: 24690–24697. doi: 10.1074/jbc.M112.377101 PMID: 22610094
14. Rosengarth A, Luecke H (2003) A calcium-driven conformational switch of the N-terminal and core domains of annexin A1. J Mol Biol 326: 1317–1325. PMID: 12595246
15. Perretti M (2003) The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol Sci 24: 574–579. PMID: 14607080
16. Babin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, et al. (2006) Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem 281: 19588–19599. PMID: 16675446
17. Yinghao RP, Kamal AM, Solito E, Flower RJ, Cooper D, et al. (2006) Annexin I and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 107: 2123–2130. PMID: 16278303
20. Perretti M, Ahiuwaia A, Harris JG, Goulding NJ, Flower RJ (1993) Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J Immunol 151: 4306–4314. PMID: 8409403

21. D’Amico M, Di Filippo C, La M, Solito E, McLean PG, et al. (2000) Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J 14: 1867–1869. PMID: 11023969

22. Dalli J, Consalvo AP, Ray V, Di Filippo C, D’Amico M, et al. (2013) Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/ lipoxin A4 receptor. J Immunol 190: 6478–6487. doi: 10.4049/jimmunol.1203000 PMID: 23686496

23. Perretti M, Getting SJ, Solito E, Murphy PM, Gao JL (2001) Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol 158: 1969–1973. PMID: 11395373

24. Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, et al. (2015) Annexin A1 counteracts chemo-kine-induced arterial myeloid cell recruitment. Circ Res 116: 827–835. doi: 10.1161/CIRCRESAHA.116.305825 PMID: 25520364

25. Schutters K, Kusters DH, Chatrou ML, Montero-Melendez T, Donners M, et al. (2013) Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells. Cell Death Differ 20: 49–56. doi: 10.1038/cdd.2012.107 PMID: 22959495

26. Andreu HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, et al. (1992) Clustering of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro. J Immunol 190: 5689–5691. doi: 10.4049/jimmunol.190.11.5689 PMID: 11630582

27. Davies JQ, Gordon S (2005) Isolation and culture of murine macrophages. Methods Mol Biol 290: 91–103. PMID: 15361657

28. Burgmaier M, Schutters K, Willems B, van der Vorst EP, Kusters D, et al. (2014) AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. J Cell Mol Med 18: 2117–2124. doi: 10.1111/jcmm.12374 PMID: 25214012

29. Pederzoli-Ribell M, Maione F, Cooper D, Al-Kashi A, Dalli J, et al. (2010) Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood 116: 4288–4296. doi: 10.1182/blood-2010-02-270520 PMID: 20705760

30. van Genderen H, Kenis H, Lux P, Ungeth L, Maassen C, et al. (2006) In vitro measurement of cell death with the annexin A5 affinity assay. Nat Protoc 1: 363–367. PMID: 17406257

31. De Saint-Hubert M, Mottaghy FM, Vunckx K, Nuyts J, Fonge H, et al. (2010) Site-specific labeling of 'second generation' annexin V with 99mTc(CO)3 for improved imaging of apoptosis in vivo. Bioorg Med Chem 18: 1356–1363. doi: 10.1016/j.bmc.2009.12.021 PMID: 20053567

32. De Saint-Hubert M, Bauwens M, Deckers N, Drummen M, Douma K, et al. (2013) In Vivo Molecular Imaging of Apoptosisand Necrosis in Atherosclerotic PlaquesUsing MicroSPECT-CT and MicroPET-CT Imaging. Mol Imaging Biol.

33. Tchaikovsky SN, Varv BJ, Rosing J, Tans G (2007) Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J Thromb Haemost 5: 2079–2086. PMID: 17666016

34. Kenis H, van Genderen H, Bennaghmouch A, Rina HA, Frederik P, et al. (2004) Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem 279: 52623–52629. PMID: 15381697

35. Ungeth L, Kenis H, Nicolaes GA, Autin L, Stoilova-McPhie S, et al. (2011) Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J Biol Chem 286: 1903–1910. doi: 10.1074/jbc.M110.163527 PMID: 21078669

36. Locatelli I, Sutti S, Jindal A, Vacciano M, Bozzola C, et al. (2014) Endogenous annexin A1 IS a novel protective determinant in nonalcoholic steatohepatitis (NASH). Hepatology.

37. Girol AP, Mimura KK, Drewes CC, Bolonheis SM, Solito E, et al. (2013) Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro. J Immunol 190: 5689–5701. doi: 10.4049/jimmunol.1202030 PMID: 23645879

38. Leoni G, Alam A, Neumann PA, Lambeth JD, Cheng G, et al. (2013) Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest 123: 443–454. doi: 10.1172/JCI65831 PMID: 23241962

39. Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7: 275ra220.

40. Vangestel C, Peeters M, Oltenfreiter R, D’Asseler Y, Staelens S, et al. (2010) In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of
phosphatidylserine-expressing cells. Nucl Med Biol 37: 965–975. doi: 10.1016/j.nucmedbio.2010.06.007 PMID: 21055628

41. Soehnlein O (2012) Multiple roles for neutrophils in atherosclerosis. Circ Res 110: 875–888. doi: 10.1161/CIRCRESAHA.111.257535 PMID: 2147339

42. Bot I, Daissromont IT, Zernecke A, van Puijvelde GH, Kram B, et al. (2014) CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol 74: 44–52. doi: 10.1016/j.jmcc.2014.04.021 PMID: 24816217

43. Doring Y, Drechsler M, Soehnlein O, Weber C (2015) Neutrophils in atherosclerosis: from mice to man. Arterioscler Thromb Vasc Biol 35: 288–295. doi: 10.1161/ATVBAHA.114.303564 PMID: 25147325

44. Bot I, Daissromont IT, Zernecke A, van Puijvelde GH, Kram B, et al. (2014) CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol 74: 44–52. doi: 10.1016/j.jmcc.2014.04.021 PMID: 24816217

45. Doring Y, Drechsler M, Soehnlein O, Weber C (2015) Neutrophils in atherosclerosis: from mice to man. Arterioscler Thromb Vasc Biol 35: 288–295. doi: 10.1161/ATVBAHA.114.303564 PMID: 25147325

46. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, et al. (2005) ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 106: 584–592. PMID: 15811956

47. Hartwig H, Silvestre Roig C, Daemen M, Lutgens E, Soehnlein O (2015) Neutrophils in atherosclerosis. A brief overview. Hamostaseologie 35: 121–127. doi: 10.5482/HAMO-14-09-0040 PMID: 25385255

48. Drechsler M, de Jong RJ, Rossaint J, Viola J, Leoni G, et al. (2014) CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol 74: 44–52. doi: 10.1016/j.jmcc.2014.04.021 PMID: 24816217

49. Doring Y, Drechsler M, Soehnlein O, Weber C (2015) Neutrophils in atherosclerosis: from mice to man. Arterioscler Thromb Vasc Biol 35: 288–295. doi: 10.1161/ATVBAHA.114.303564 PMID: 25147325